RenovoRx, Inc. (RNXT) Stock Price & Growth Analysis - Tweevest

New

Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now

You have successfully sign out

RenovoRx, Inc.

RNXT

NASDAQ

Unprofitable

Unprofitable

24M

Biotechnology

Next Earning date - 11 Nov 2024

24M

Biotechnology

Next Earning date - 11 Nov 2024

1.00USD

0.00 ( 0.00%)

Relative Strenght

15

Volume Buzz

-70%

Earning Acce

No

Dist 52w H.

57%

Quote Panel

Updated October 19, 2024

1W 0.00 % 1M -18.03 % 3M -15.25 % 1Y -13.79 %

Key Metrics

Market Cap
23.99M
Shares Outstanding
23.99M
Share in Float
23.53M
Dividende
0

Earning Date
11 Nov 2024
Price Target
1
Average Volume
31962
Beta
0.984

Range
0.531-2.35
Industry
Biotechnology
Website
https://renovorx.com
Sector
Healthcare

Fundamentals

N/A

P/E Ratio

0.00x

P/S Ratio

2.67x

P/B Ratio

0.0

Debt/Equity

0.0%

Net Margin

$-0.6

EPS

How RNXT compares to sector?

P/E Ratio

Relative Strength

RNXT

Sector

loading...

Top 5 RS in Group

Symbol	Company	RS	5-Day Perf.

Forecast

$28M

NaN%

2025-Revenue

$0.41

-316%

2025-EPS

0

Analyst rating

No Data Available

Last analyst upgrade/downgrade

Ascendiant

initialise

Previous: Not converted

2024-06-17

Now: Buy

Maxim Group

upgrade

Previous: Not converted

2024-02-29

Now: Buy

Earnings Growth

YoY

Current

Estimates

Q3.22

N/A

-0.24
vs -0.27

Q4.22

N/A

-0.23
vs -0.12

Q1.23

N/A

-0.36
vs -0.33

Q2.23

N/A

-0.22
vs -0.29

Q3.23

N/A

-0.27
vs -0.24

Q4.23

N/A

-0.31
vs -0.23

Q1.24

N/A

-0.07
vs -0.36

Q2.24

N/A

-0.10
vs -0.22

Q3.24

N/A

-0.12
vs -0.27

Q4.24

N/A

-0.10
vs -0.31

Sales Growth

YoY

Current

Estimates

Q1.22

NA

NA vs NA

Q2.22

NA

NA vs NA

Q3.22

NA

NA vs NA

Q4.22

NA

NA vs NA

Q1.23

NA

NA vs NA

Q2.23

NA

NA vs NA

Q3.23

NA

NA vs NA

Q4.23

NA

NA vs NA

Q1.24

NA

NA vs NA

Q2.24

NA

NA vs NA

Return on Equity

QoQ

Q3.22

-26%

-0.26
vs -0.25

Q4.22

-34%

-0.34
vs -0.26

Q1.23

-100%

-1.00
vs -0.34

Q2.23

-196%

-1.96
vs -1.00

Q3.23

-23683%

-236.83
vs -1.96

Q4.23

+108%

1.08
vs -236.83

Q1.24

-61%

-0.61
vs 1.08

Q2.24

-26%

-0.26
vs -0.61

Institutionnal Ownership

QoQ

Q3.22

12

12
vs 9

33%

Q4.22

11

11
vs 12

-8%

Q1.23

12

12
vs 11

9%

Q2.23

9

9
vs 12

-25%

Q3.23

14

14
vs 9

56%

Q4.23

11

11
vs 14

-21%

Q1.24

9

9
vs 11

-18%

Q2.24

16

16
vs 9

78%

Earnings Growth

Latest News

RNXT

globenewswire.com

8 hours ago

RenovoRx Increases Production of FDA-Cleared RenovoCath® Delivery System in Response to Strong Demand from Oncology and Interventional Radiology Physicians

RNXT

globenewswire.com

8 hours ago

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology Highlighting TAMP™ for Targeted Treatment of Locally Advanced Pancreatic Cancer

RNXT

globenewswire.com

8 hours ago

RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 26th Annual Global Investment Conference on September 9, 2024 in New York

RNXT

globenewswire.com

8 hours ago

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RNXT

globenewswire.com

8 hours ago

RenovoRx Announces Acceptance for Publication in the International Peer-Reviewed Journal, The Oncologist®

RNXT

globenewswire.com

8 hours ago

University of Nebraska Medical Center Launches Patient Enrollment for RenovoRx's Pivotal Phase III TIGeR-PaC Clinical Trial

New Feature Coming Soon, Stay Tuned!

Shape

Shape